Luisa Manning

RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer

Zachary Sethna, Pablo Guasp, Charlotte Reiche et al. · Nature · 2025 · 165 citations · Full text

Cancer Immunosurveillance, Pancreatic Cancer, Immunology +5

Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial

Rodney P. Rocconi, Elizabeth A. Grosen, Sharad Ghamande et al. · The Lancet Oncology · 2020 · 112 citations

Medicine, Immunology, Gynecology +6

Phase II study of Vigil® DNA engineered immunotherapy as maintenance in advanced stage ovarian cancer

Jonathan Oh, Minal Barve, Carolyn M. Matthews et al. · Gynecologic Oncology · 2016 · 88 citations

Vigil® Dna, Medicine, Immunology +9

Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial

Juanita Lopez, Thomas Powles, Fadi Braiteh et al. · Nature Medicine · 2025 · 71 citations · Full text

Tumoral Pathology, Medicine, Metronomic Therapy +7

Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancer

Rodney P. Rocconi, Bradley J. Monk, Adam Walter et al. · Gynecologic Oncology · 2021 · 35 citations

Radiation Oncology, Homologous Recombination Proficient, Cell Therapy +8